Cosmo Pharmaceuticals S.p.A. is offering to acquire a 2002 Roche spin-out for CHF 41.3 million (€27.4 million) giving it access to a novel treatment for pain, and research and development assets that could lead to drugs for urological indications.
Phytopharm Plc has obtained underwriting commitments to increase its share capital by 267% following the announcement in October 2009 of favourable results from two studies of Cogane, the company’s treatment for Parkinson’s disease.
Curetis AG, a German diagnostics company, has raised €18.5 million in a Series A round in order to complete development of its diagnostic products for detecting severe infectious diseases. The round was led by Life Sciences Partners.
AstraZeneca Plc is to pay $200 million upfront for rights to a candidate product for depression that works by modulating the activity of various neuronal nicotinic receptor subtypes. The agreement is with Targacept Inc of the US.
Argen-x BV, a Dutch biopharmaceutical company that is discovering and developing a new type of antibody, has raised an additional €3 million in a Series A equity financing round, bringing the total raised for the round to €12.5 million.
Bavarian Nordic A/S has announced plans to raise DKK 250 to 300 million (€34 to 40 million) in a rights issue in order to support its biodefence and cancer programmes. The issue is expected to be completed at the beginning of 2010.
Biomedical Diagnostics, a French in vitro diagnostics company that produces products to detect auto-immune diseases, has raised €3 million in a private share placement led by Truffle Capital and AGF Private Equity.
NicOx SA of France has launched a rights issue of approximately €70 million following the successful completion of a €30 million private placement. An NDA for the company’s lead drug has been filed with the Food and Drug Administration.
Clavis Pharma ASA of Norway has reached an agreement to partner its candidate drug for pancreatic cancer with a start-up oncology company in the US in a deal valued at up to $380 million. The partner is Clovis Oncology Inc of Colorado.
Oxagen Ltd, a privately held UK company researching treatments for inflammation and allergies, has obtained a £16 million, Series C financing from a syndicate led by Novartis Venture Funds.